AHA: Proton Pump Inhibitors May Up Post-PCI Mortality
In patients with drug-eluting stents, omeprazole and pantaprazole linked to higher risk of death
20 nov 2009-- In patients who undergo percutaneous coronary intervention with drug-eluting stents, use of proton pump inhibitors is associated with an increased risk of all-cause mortality, according to research presented this week at the American Heart Association Scientific Sessions, held from Nov. 14 to 18 in Orlando, Fla.
Joseph M. Sweeny, M.D., of Mount Sinai Medical Center in New York City, and colleagues conducted a retrospective cohort study of 8,311 patients, including 1,385 (17 percent) who took proton pump inhibitors.
During a mean two years of follow-up, 602 patients died. The researchers found that use of proton pump inhibitors was associated with an increased risk of death (multivariable adjusted hazard ratio, 1.30). They also found that the risk was elevated for those taking omeprazole and pantoprazole (multivariable adjusted hazard ratios, 1.72 and 1.54, respectively) compared to those taking esomeprazole and lansoprazole (multivariable adjusted hazard ratios, 0.97 and 1.02, respectively).
"Proton pump inhibitor use was associated with a non-significant increased risk of 30-day stent thrombosis and target lesion revascularization following percutaneous coronary intervention," the authors conclude.
Two co-authors reported financial relationships with pharmaceutical companies.